PMGC Holdings (ELAB) Income from Discontinued Operations (2024 - 2026)
PMGC Holdings' (ELAB) quarterly Income from Discontinued Operations came in at $17590.0 in Q2 2026, up 2.66% year-over-year from $17135.0 in Q2 2025, and down 9.8% quarter-over-quarter from $19501.0 in Q1 2026.
Powered by 
Analysis
PMGC Holdings (ELAB) Income from Discontinued Operations (2024 - 2026) Analysis & Trends
PMGC Holdings has disclosed Income from Discontinued Operations across 3 years of filings, most recently posting $17590.0 for Q2 2026.
- In Q2 2026, Income from Discontinued Operations rose 2.66% year-over-year to $17590.0; the TTM figure through Jun 2026 stood at $80527.0 (up 115.29% YoY), while the FY2025 annual figure was $32927.0, up 101.48% from the prior year.
- Income from Discontinued Operations came in at $17590.0 for Q2 2026 at PMGC Holdings, down from $19501.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of $21738.0 in Q4 2025 to a low of -$859580.0 in Q2 2024.
- Average Income from Discontinued Operations over 3 years is -$145097.3, with a median of $17135.0 recorded in 2025.
- The largest YoY upside for Income from Discontinued Operations was 170.54% in 2026 against a maximum downside of 2.66% in 2026.
- Over 3 years, Income from Discontinued Operations stood at -$216910.0 in 2024, then jumped by 110.02% to $21738.0 in 2025, then dropped by 19.08% to $17590.0 in 2026.
- Per Business Quant data, the three most recent Income from Discontinued Operations figures were $17590.0 in Q2 2026, $19501.0 in Q1 2026, and $21738.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.11 Bn | 193.12 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 178.91 Bn | 175.73 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.35 Bn | 123.50 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.84 Bn | 73.85 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.06 Bn | 55.87 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.08 Bn | 47.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.32 Bn | 30.01 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.70 Bn | 30.41 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.48 Bn | 29.48 Bn | 1.16 Mn | - |
| 10 | PMGC Holdings | 2.23 Mn | -16.56 Mn | 385,691.00 | 17,590.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17,590.00 |
| Mar 31, 2026 | 19,501.00 |
| Dec 31, 2025 | 21,738.00 |
| Sep 30, 2025 | 21,698.00 |
| Jun 30, 2025 | 17,135.00 |
| Mar 31, 2025 | -27,644.00 |
| Dec 31, 2024 | -216,910.00 |
| Sep 30, 2024 | -299,404.00 |
| Jun 30, 2024 | -859,580.00 |